112 related articles for article (PubMed ID: 17630660)
1. Incidence and predictors of clinically driven target lesion revascularization from bare-metal stents to drug-eluting stents.
Park SJ
Catheter Cardiovasc Interv; 2007 Aug; 70(2):184. PubMed ID: 17630660
[No Abstract] [Full Text] [Related]
2. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
[TBL] [Abstract][Full Text] [Related]
3. Treatment of drug-eluting stent restenosis: a sandwich may not be the best combo.
Belardi J
Catheter Cardiovasc Interv; 2008 Apr; 71(5):599. PubMed ID: 18360848
[No Abstract] [Full Text] [Related]
4. Transition from bare metal to drug eluting stenting in contemporary US practice: effect on incidence and predictors of clinically driven target lesion revascularization.
Jonas M; Resnic FS; Levin AD; Arora N; Rogers CD
Catheter Cardiovasc Interv; 2007 Aug; 70(2):175-83. PubMed ID: 17630659
[TBL] [Abstract][Full Text] [Related]
5. Drug-eluting stent in saphenous vein graft lesions.
Kornowski R
Catheter Cardiovasc Interv; 2008 Jun; 71(7):894-5. PubMed ID: 18498140
[No Abstract] [Full Text] [Related]
6. Long-term clinical outcomes of real-world experience using sirolimus-eluting stents in saphenous vein graft disease.
Ramana RK; Ronan A; Cohoon K; Homan D; Sutherland J; Steen L; Liu J; Loeb H; Lewis BE
Catheter Cardiovasc Interv; 2008 Jun; 71(7):886-93. PubMed ID: 18412238
[TBL] [Abstract][Full Text] [Related]
7. What kind of stent for you today and how would you like it prepared?
Butman SM
Catheter Cardiovasc Interv; 2007 Aug; 70(2):173-4. PubMed ID: 17630654
[No Abstract] [Full Text] [Related]
8. Drug-eluting stents are associated with similar cardiovascular outcomes when compared to bare metal stents in the setting of acute myocardial infarction.
Slottow TL; Steinberg DH; Roy P; Javaid A; Buch AN; Okabe T; Xue Z; Smith K; Torguson R; Pichard AD; Satler LF; Suddath WO; Kent KM; Waksman R
Cardiovasc Revasc Med; 2008; 9(1):24-8. PubMed ID: 18206634
[TBL] [Abstract][Full Text] [Related]
9. One-year clinical results and total costs of drug-eluting stents implantation in multivessel coronary artery disease.
Varani E; Balducelli M; Vecchi G; Aquilina M; Maresta A
J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):596-601. PubMed ID: 17667030
[TBL] [Abstract][Full Text] [Related]
10. Value and limitations of target-vessel ischemia in predicting late clinical events after drug-eluting stent implantation.
Zellweger MJ; Kaiser C; Brunner-La Rocca HP; Buser PT; Osswald S; Weiss P; Mueller-Brand J; Pfisterer ME;
J Nucl Med; 2008 Apr; 49(4):550-6. PubMed ID: 18344439
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel-eluting stents for the treatment of complex coronary lesions: immediate and 12-month results.
Sheiban I; Ballari GP; Moretti C; Marra WG; Meliga E; Omedè P; Sciuto F; Trevi GP
J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):582-8. PubMed ID: 17667028
[TBL] [Abstract][Full Text] [Related]
12. Trifurcation left main coronary artery percutaneous revascularization--pushing catheters and envelopes.
Moliterno DJ
Catheter Cardiovasc Interv; 2009 Jan; 73(1):32-3. PubMed ID: 19089933
[No Abstract] [Full Text] [Related]
13. Clinical presentation of patients with late target lesion revascularization.
Kaneda H
Catheter Cardiovasc Interv; 2008 Nov; 72(5):749. PubMed ID: 18942148
[No Abstract] [Full Text] [Related]
14. Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007.
Daemen J; Simoons ML; Wijns W; Bagust A; Bos G; Bowen JM; Braunwald E; Camenzind E; Chevaliers B; DiMario C; Fajadeto J; Gitt A; Guagliumi G; Hillege HL; James S; Jüni P; Kastrati A; Kloth S; Kristensen SD; Krucoff M; Legrand V; Pfisterer M; Rothman M; Serruys PW; Silber S; Steg PG; Tariah I; Wallentin L; Windecker SW; Aimonetti A; Allocco D; Berenger M; Boam A; Calle JP; Campo G; Carlier S; de Schepper J; Di Bisceglie G; Dobbels H; Farb A; Ghislain JC; Hellbardt S; ten Hoedt R; Isaia C; de Jong P; Lekehal M; LeNarz L; Mhullain FN; Nagai H; Patteet A; Paunovic D; Potgieter A; Purdy I; Raveau-Landon C; Ternstrom S; Van Wuytswinkel J; Waliszewski M;
EuroIntervention; 2009 Jan; 4(4):427-36. PubMed ID: 19284063
[No Abstract] [Full Text] [Related]
15. Drug eluting stents in AMI: keep the data coming.
Vetrovec GW
Catheter Cardiovasc Interv; 2008 May; 71(6):770-1. PubMed ID: 18412075
[No Abstract] [Full Text] [Related]
16. A sweet summer for drug-eluting stents in patients with diabetes mellitus.
Costa MA
Catheter Cardiovasc Interv; 2008 Nov; 72(5):610-1. PubMed ID: 18949774
[No Abstract] [Full Text] [Related]
17. Is there a preferable DES in diabetic patients? A critical appraisal of the evidence.
Byrne RA; Kastrati A
Catheter Cardiovasc Interv; 2008 Dec; 72(7):944-9. PubMed ID: 19021280
[TBL] [Abstract][Full Text] [Related]
18. "Neither horseshoes nor hand grenades"--does close count in percutaneous coronary revascularization?
Bailey SR
Catheter Cardiovasc Interv; 2008 Oct; 72(4):457-8. PubMed ID: 18819143
[No Abstract] [Full Text] [Related]
19. Percutaneous revascularization of the "unprotected" left main during acute myocardial infarction: "Dare to struggle! Dare to win!".
Morrison DA
Catheter Cardiovasc Interv; 2009 Jan; 73(1):22-4. PubMed ID: 19089931
[No Abstract] [Full Text] [Related]
20. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
